)
Kumar Gaurav is a business journalist driven by a profound passion for the economy, culture, and human rights. He covers market movements, IPOs, regulatory updates, and major developments in equity markets. Having earned a Master's degree in Journalism from the University of Delhi's Delhi School of Journalism, Kumar previously worked with ET Now and Financial Express, focusing on primary and secondary markets. His dedication lies in uncovering the connections between the markets and the human experience, offering a nuanced perspective on the world of business.
Kumar Gaurav is a business journalist driven by a profound passion for the economy, culture, and human rights. He covers market movements, IPOs, regulatory updates, and major developments in equity markets. Having earned a Master's degree in Journalism from the University of Delhi's Delhi School of Journalism, Kumar previously worked with ET Now and Financial Express, focusing on primary and secondary markets. His dedication lies in uncovering the connections between the markets and the human experience, offering a nuanced perspective on the world of business.
A sharper-than-expected decline in PVC prices following the lack of anti-dumping duty (ADD) and the withdrawal of BIS norms has further worsened the operating environment
Stocks to Watch Today, November 21, 2025: Nestle India, Adani Ports, 360 ONE WAM, Alkem Laboratories, JSW Energy, and Zaggle Prepaid are among the top stocks to remain in focus today
Stocks to Watch Today, November 18, 2025: Tata Power Company, TVS Motor Company, Emcure Pharma, AstraZeneca Pharma, JSW Energy, JSW Cement, and WPIL are among the top stocks to remain in spotlight
Nuvama has retained its 'Buy' tag on the stock, revising the target price to ₹750 per share from ₹700 per share, following a 32 per cent year-on-year jump in PAT to ₹61.6 crore in Q2FY26
Stocks to Watch Today, November 17, 2025: Marico, Glenmark Pharma, FirstCry, Siemens, Dish TV, Alembic Pharma, Cyient, and Websol Energy System are among the top stocks to remain in focus today
Domestic mutual funds extended their record-breaking run, with ownership climbing to an all-time high of 10.9 per cent (Active: 9.0 per cent, Passive: 1.0 per cent).
MOFSL and JM Financial retained their Buy ratings, while Nuvama upgraded Biocon to Buy from Hold after the company posted a net profit of ₹85 crore in Q2FY26
While Choice has reiterated its Buy rating, citing resilient operational performance & steady market leadership, Nuvama has maintained 'Reduce' on valuation concerns and moderation in industry growth
Analysts believe the company is well-positioned for "sustained, high-quality growth," reinforcing long-term earnings visibility
Groww IPO Listing: Shares of Groww are set to make their D-Street debut tomorrow, November 12, 2025. Here's what the latest grey market premium (GMP) hints at regarding the tentative listing
Once listed, the CV stock will debut under a separate ticker, allowing independent trading of the two Tata Motors companies
Emkay Global Financial Services has retained its 'Add' rating on the insurance behemoth, while Motilal Oswal Financial Services (MOFSL) has maintained its 'Buy' recommendation
According to Nuvama, Aurobindo's Q2FY26 revenue and Ebitda were ahead of consensus estimates by 2 per cent and 1 per cent, respectively, though PAT missed expectations by about 5 per cent
The share of FIIs declined further to a 13-year low of 16.71 per cent as on September 30, 2025 (down from 17.05 per cent on June 30, 2025), while MF holdings rose to an all-time high of 10.93 per cent
With operational cell/module capacity of 5.4 GW/16.1 GW in India, WEL, analysts believe, towers domestic competitors and enjoys a formidable India capacity market share of 21.6 per cent/13.3 per cent
Once the allotment is finalised, applicants can verify their allotment status online through the official websites of the BSE, NSE, or MUFG Intime India, the registrar to the issue
While Groww IPO attracts moderate interest, analysts debate if listed peers offer better value for money
With larger generic companies facing growth challenges in the US in FY27E, Ajanta Pharma, analysts believe, offers a strong investment opportunity, driven by its branded market growth
As investors await the D-Street debut of the demerged entity, here are the key details they should know
The company launched its initial public offering (IPO) on Friday, October 31, aiming to raise ₹7,278.02 crore from primary markets